On Monday, Roche Holding AG (RHHBY) completed its purchase of Carmot Therapeutics Inc. The acquisition involved buying all outstanding shares and options of Carmot for $2.7 billion.
Additionally, Carmot's equity holders may receive up to $400 million based on the fulfillment of specific milestones.
This acquisition grants Roche access to Carmot's current R&D portfolio, including clinical and pre-clinical assets, as well as exclusive rights to Carmot's Chemotype Evolution discovery platform in metabolism. This move is set to bolster Roche's R&D endeavors and portfolio in the realms of cardiovascular and metabolic diseases.
Following the completion of the acquisition, Carmot and its employees will become part of the Roche Group under the Pharmaceuticals Division.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.